The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

Genmab Announces Financial Results for the First Quarter of 2024May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025HighlightsEPKINLY® (epcoritamab) approved by ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza), the first medicine licensed ...

Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional ...